Pinealon
Grade CRussian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.
Mechanism of Action
Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.
Typical Protocol
Dose
1–10 mg
Frequency
Daily
Duration
10–20 day cycles, 1–2× per year
Timing
Morning
Route
Intranasal or subcutaneous
Half-life
Short, hours
Educational reference only — not medical advice.
Reported Benefits
- Reported neuroprotection in rodent ischemia models
- Reduced oxidative stress markers
- Subjective cognitive and sleep improvements (anecdotal)
Side Effects
- Largely unknown long-term
- Injection site or nasal irritation
Contraindications
- Active malignancy
- Pregnancy
Known Interactions
Other bioregulator peptidesOften stacked; interactions not characterized.
References
Comparison vs Alternatives
All Peptides →| Attribute | PinealonThis page | Dihexa | Semaglutide |
|---|---|---|---|
| Evidence | Grade C | Grade C | Grade A |
| Category | Cognitive | Cognitive | Metabolic |
| Best for | Cognitive resilience (research) | Cognitive plasticity (preclinical) | GLP-1 receptor agonist |
| Typical dose | 1–10 mg | 8–45 mg (anecdotal) | 0.25 → 2.4 mg |
| Frequency | Daily | Daily | Weekly |
| Route | Intranasal or subcutaneous | Oral or transdermal (research) | Subcutaneous weekly (oral form available) |
| Legal status | Research chemical; not approved for human therapeutic use. | Research chemical. Not approved for human use. Significant unknown oncologic risk. | FDA-approved (Ozempic, Wegovy). Prescription required. |
| Action | Current page | View → | View → |